A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer.

Details

Ressource 1Download: Lehr_22186896.pdf (927.73 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_3676BCF1B3D9
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer.
Journal
Nature Communications
Author(s)
Reppert S., Boross I., Koslowski M., Türeci O., Koch S., Lehr H.A., Finotto S.
ISSN
2041-1723 (Electronic)
ISSN-L
2041-1723
Publication state
Published
Issued date
12/2011
Volume
2
Pages
600
Language
english
Notes
accessibvle en ligne dès déc. 2011
Abstract
Lung cancer is the leading cause of cancer deaths worldwide. The cytokine interleukin-17A supports tumour vascularization and growth, however, its role in lung cancer is unknown. Here we show, in the lungs of patients with lung adenocarcinoma, an increase in interleukin-17A that is inversely correlated with the expression of T-bet and correlated with the T regulatory cell transcription factor Foxp3. Local targeting of interleukin-17A in experimental lung adenocarcinoma results in a reduction in tumour load, local expansion of interferon-γ-producing CD4(+) T cells and a reduction in lung CD4(+)CD25(+)Foxp3(+) regulatory T cells. T-bet((-/-)) mice have a significantly higher tumour load compared with wild-type mice. This is associated with the local upregulation of interleukin-23 and induction of interleukin-17A/interleukin-17R-expressing T cells infiltrating the tumour. Local anti-interleukin-17A antibody treatment partially improves the survival of T-bet((-/-)) mice. These results suggest that local anti-interleukin-17A antibody therapy could be considered for the treatment of lung tumours.
Pubmed
Web of science
Open Access
Yes
Create date
05/01/2012 11:07
Last modification date
20/08/2019 13:24
Usage data